Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B

Foghorn Therapeutics Inc.

Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).
Selective CBP degrader CBPd-171 advancing to non-GLP toxicology studies in Q4 2025; IND-ready in 2026 for EP300-mutant cancers and ER+ breast cancer.
Selective EP300 degrader demonstrates efficacy in >70% of hematological malignancies and IMiD-resistant multiple myeloma without thrombocytopenia.
All three programs leverage novel degrader technology to overcome historical challenges of high homology with ARID1A, CBP/EP300.
Company hosting virtual investor event on October 30, 2025 at 12 p.m. ET to present data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.